Categories
| Category | |
|---|---|
| Health Conditions and Concerns | 75% |
| Health | 25% |
Explore sites in same category:
- ogorimii-med.net Rank 1.4M. Estimated value 1,512$
- ocrahope.org Rank 781.7K. Estimated value 2,760$
- myvision.org Rank 439.1K. Estimated value 4,932$
- gluten.org Rank 887.9K. Estimated value 2,424$
- veri.co Rank 646.5K. Estimated value 3,336$
- kesimpta.com Rank 1.3M. Estimated value 1,668$
- dr-hips.com Rank 1M. Estimated value 2,232$
- ito-jibika.net Rank 1.1M. Estimated value 1,968$
- presspogo.com Rank 663.9K. Estimated value 3,252$
- myeczemateam.com Rank 1.5M. Estimated value 1,392$
Keyword Suggestion
Domain Informations
Brukinsa.com lookup results from whois.registrar.amazon server:
- Domain created: 2017-09-13T13:19:33Z
- Domain updated: 2025-08-09T13:22:42Z
- Domain expires: 2026-09-13T13:19:33Z 0 Years, 250 Days left
- Website age: 8 Years, 114 Days
- Registrar Domain ID: 2162427762_DOMAIN_COM-VRSN
- Registrar Url: http://registrar.amazon.com
- Registrar WHOIS Server: whois.registrar.amazon
- Registrar Abuse Contact Email: [email protected]
- Registrar Abuse Contact Phone: +1.2024422253
- Name server:
- NS-1051.AWSDNS-03.ORG
- NS-1976.AWSDNS-55.CO.UK
- NS-223.AWSDNS-27.COM
- NS-747.AWSDNS-29.NET
Network
- inetnum : 162.158.0.0 - 162.159.255.255
- name : CLOUDFLARENET
- handle : NET-162-158-0-0-1
- status : Direct Allocation
- created : 2010-07-09
- changed : 2024-11-25
- desc : All Cloudflare abuse reporting can be done via https://www.cloudflare.com/abuse,Geofeed: https://api.cloudflare.com/local-ip-ranges.csv
Owner
- organization : Cloudflare, Inc.
- handle : CLOUD14
- address : Array,San Francisco,CA,94107,US
Abuse
- handle : ABUSE2916-ARIN
- name : Abuse
- phone : +1-650-319-8930
- email : [email protected]
Technical support
- handle : ADMIN2521-ARIN
- name : Admin
- phone : +1-650-319-8930
- email : [email protected]
| Domain Provider | Number Of Domains |
|---|---|
| godaddy.com | 286730 |
| namecheap.com | 101387 |
| networksolutions.com | 69118 |
| tucows.com | 52617 |
| publicdomainregistry.com | 39120 |
| whois.godaddy.com | 32793 |
| enomdomains.com | 23825 |
| namesilo.com | 21429 |
| domains.google.com | 21384 |
| cloudflare.com | 20573 |
| gmo.jp | 18110 |
| name.com | 17601 |
| fastdomain.com | 14708 |
| register.com | 13495 |
| net.cn | 12481 |
| ionos.com | 12416 |
| ovh.com | 12416 |
| gandi.net | 12305 |
| registrar.amazon.com | 12111 |
Host Informations
- IP address: 162.159.134.42
- Location:
- Latitude:
- Longitude:
- Timezone:
Site Inspections
Port Scanner (IP: 162.159.134.42)
Spam Check (IP: 162.159.134.42)
Similar sites
Websites Listing
We found Websites Listing below when search with brukinsa.com on Search Engine
Brukinsa: Uses, side effects, interactions, and more
2020-05-15 · Brukinsa is a Bruton’s tyrosine kinase (BTK) inhibitor. It forms a covalent bond in the BTK active site and leads to inhibition of BTK activity. This leads to inhibition of cell signaling ...
Medicalnewstoday.comBrukinsa oral: Uses, Side Effects, Interactions, Pictures
Brukinsa 80 Mg Capsule Antineoplastic - Protein-Tyrosine Kinase Inhibitors - Uses, Side Effects, and More Generic Name: zanubrutinib . This medication is …
Webmd.comFDA accepts sNDA for Brukinsa to treat chronic lymphocytic …
2022-02-23 · This is an important milestone in Brukinsa’s global registration program. With superiority in investigator-assessed ORR over ibrutinib in ALPINE for relapsed or refractory patients and in PFS over chemoimmunotherapy in the SEQUOIA study for treatment-naïve patients, Brukinsa has demonstrated its potential to improve treatment outcomes for CLL …
Medthority.comBRUKINSA: Bula original, obtida diretamente da ANVISA | Bula.Gratis
BRUKINSA® é uma pequena molécula que inibe a BTK (BTK é uma enzima que sinaliza as vias do receptor de antígeno das células B (BCR) e do receptor de citocina). A substância ativa do BRUKINSA®, zanubrutinibe, forma uma ligação química com um resíduo de cisteína no sítio ativo da BTK, levando à inibição da atividade da enzima BTK ...
Bula.gratisAll Therapy Areas - Hematology, Brukinsa
2022-06-14 · All Therapy Areas - Hematology, Brukinsa Article. Top-line results for bexmarilimab across 10 advanced solid tumors. Epilepsy: Article More options for people living with rare form of epilepsy; Immunotherapies: Article Dragonfly inks strategic research collaboration with Gilead; Research: Article GSK sees LifeMine as a fungi to be around; Coronavirus: Article Three …
Thepharmaletter.comZanubrutinib - Wikipedia
Zanubrutinib, sold under the brand name Brukinsa, is a medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), and marginal zone lymphoma (MZL). Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor. It is given by mouth.. It was approved for medical use in the United States in November 2019.
En.wikipedia.orgBeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 …
2022-06-13 · Over the past year, BeiGene has achieved approval for BRUKINSA in five countries in the MENA region including Saudi Arabia, United Arab Emirates, Kuwait, Bahrain and Qatar," said Mohammed Al ...
Finance.yahoo.comBeiGene Announces BRUKINSA (zanubrutinib) Approval in …
2022-04-28 · BRUKINSA is supported by a broad clinical program which includes more than 3,900 subjects in 35 trials across 28 markets. To date, BRUKINSA has received more than 20 approvals covering more than ...
Finance.yahoo.comBeiGene Announces First Regulatory Approval in Australia for …
2021-10-07 · About BRUKINSA ® (zanubrutinib) BRUKINSA is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. Because new BTK is continuously ...
Uk.news.yahoo.comBeiGene Announces Approval in - GuruFocus.com
2021-07-26 · GuruFocus Article or News written by Business Wire and the topic is about:
Gurufocus.comBeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 …
2014-06-22 · BRUKINSA is supported by a broad clinical program which includes more than 3,900 subjects in 35 trials across 28 markets. To date, BRUKINSA has received more than 20 approvals covering 50 ...
Theglobeandmail.comzanubrutinib | CADTH
2021-03-23 · 08-Sep-21. CADTH responses on draft review report (s) provided to sponsor. 29-Sep-21. Expert committee meeting (initial) 13-Oct-21. Draft recommendation issued to sponsor. 26-Oct-21. Draft recommendation posted for stakeholder feedback. 04-Nov-21.
Cadth.caBeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 …
2022-06-13 · BRUKINSA is supported by a broad clinical program which includes more than 3,900 subjects in 35 trials across 28 markets. To date, BRUKINSA has received more than 20 approvals covering 50 countries and regions, including the United States, China, the EU, and Great Britain, Canada, Australia and additional international markets. Currently, more ...
Biospace.comIRC Determines BRUKINSA® (Zanubrutinib) Demonstrates …
2022-04-11 · BRUKINSA is supported by a broad clinical program which includes more than 3,900 subjects in 35 trials across 28 markets. To date, BRUKINSA has received more than 20 approvals covering more than ...
Businesswire.com2022-06-13 | NDAQ:BGNE | Press Release | BeiGene Ltd.
2022-06-13 · BRUKINSA is supported by a broad clinical program which includes more than 3,900 subjects in 35 trials across 28 markets. To date, BRUKINSA has received more than 20 approvals covering 50 countries and regions, including the United States, China, the EU, and Great Britain, Canada, Australia and additional international markets. Currently, more ...
Stockhouse.comBeiGene Announces Health Canada Approval for BRUKINSA® …
2022-03-03 · About BRUKINSA. BRUKINSA is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. Because new BTK is continuously synthesized, BRUKINSA ...
Financialpost.comBeiGene Announces Authorisation of BRUKINSA (zanubrutinib) …
2021-12-15 · BRUKINSA (zanubrutinib) is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other agents to treat various B-cell malignancies. Because new BTK is continuously synthesized, BRUKINSA was specifically …
Marketscreener.comBeiGene Announces BRUKINSA® (Zanubrutinib) Approved for …
2021-10-10 · About BRUKINSA ® (zanubrutinib) BRUKINSA is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. Because new BTK is continuously ...
Ca.finance.yahoo.comBeiGene Announces BRUKINSA Approved for Treatment of …
About BRUKINSA. BRUKINSA is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. Because new BTK is continuously synthesised, BRUKINSA ...
Worldpharmatoday.comBeiGene Announces Approval in Canada of BRUKINSA® …
2021-07-26 · About BRUKINSA ® (zanubrutinib) BRUKINSA is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. Because new BTK is continuously synthesized, BRUKINSA …
Financialpost.com
Domains Expiration Date Updated
| Site | Provider | Expiration Date |
|---|---|---|
| cosplaythots.com | publicdomainregistry.com | -3 Years, -327 Days |
| irexpo.net | publicdomainregistry.com | -3 Years, -332 Days |
| atda.org | tucows.com | -1 Years, -109 Days |
| martellosecurity.com | registrar.amazon.com | -2 Years, -313 Days |
| teknosacell.com | ihs.com.tr | -2 Years, -335 Days |
| laminarprojects.com | godaddy.com | -1 Years, -75 Days |
| vaxxitek.com | networksolutions.com | -3 Years, -261 Days |
| namzya.com | godaddy.com | -2 Years, -244 Days |
| sarahmakeup37.com | name.com | -3 Years, -197 Days |
| quzhihu.com | godaddy.com | -3 Years, -7 Days |